Selected Recent Articles

• Monthly Dosing Drug Raises Hopes and Concerns.  (July 2016, MedPage Today)
• Long-acting injectable drugs work well for HIV maintenance therapy.  (July 2016, AIDSmap)
• What we’re learning about new PrEP drugs and delivery methods at AIDS 2016.  (July 2016, Beta Blog)
• Long-acting agents may increase number of patients on therapy, bring new people into care.  (July 2016, Healio)
• Five Exciting HIV Prevention Studies We’re Paying Attention to.  (June 2016, Beta Blog)
• Weekly PRO 140 Antibody Injections Successfully Combat HIV in Some.  (June 2016, Poz); related coverage from AIDSmap
• Injectable antiretrovirals: The future of HIV management? (June 2016, Healio)
• $75K Campbell Grant to Study Long-Acting Treatment That Targets HIV Reservoirs.  (May 2016, Poz)
• Studies Begin to Test Long-Acting Antibody Infusions for HIV Prevention.  (April 2016, Poz); related coverage from NIAID
• Advances reported in long-acting PrEP.  (April 2016, Project Inform)
• Long-acting oral antiretroviral MK-8591 could represent ‘paradigm shift’ in HIV treatment and prophylaxis.  (April 2016, AIDSmap)
• Men Are Not Macaques and Other Lessons from Long-Acting PrEP Study.  (March 2016, TheBodyPro)
• Injectable Long-Acting Isentress as PrEP Protects Mice Against Vaginal HIV Exposure.  (March 2016, Poz)
• New NRTI MK-8591 (EFdA): weekly oral dosing and once-yearly slow-release dosing has potential for HIV treatment and PrEP.  (March 2016, HIV Treatment Bulletin)
• Injectable long-acting cabotegravir shows promise as PrEP in early safety trial (February 2016, Poz); related coverage from AIDSmap and abstract from 2016 Retrovirus Conference
• Long-acting injectable cabotegravir + rilpivirine works well as HIV maintenance therapy.  (February 2016, AIDSmap); related coverage from Poz and TheBody
• What is a drug “tail,” and what does it have to do with long-acting PrEP?  (February 2016, Beta Blog)
• What’s on the horizon? New PrEP options presented at Retrovirus Conference 2016.  (February 2016, Beta Blog)
• IV and Injectable HIV Treatments Are Much Discussed – But Won’t Be Here Anytime Soon.  (January 2016, Journal Watch)
• ViiV and Janssen Secure Plans to Develop Long-Acting HIV Treatment.  (January 2016, Poz)
• Four- and Eight-Week HIV Treatments Show Promise.  (November 2015, Poz)
• Weekly Injectable HIV Antibody Treatment Shows Promise.  (August 2015, Poz)
• An Update on the Pipeline of Antibodies, Long-Acting Antiretrovirals and Vaccines.  (August 2015, AVAC)
• PrEP-Delivering Subdermal Implant Shows Promise in Animal Study.  (May 2015, Poz)
• Injectable PrEP: The Next Order of the Day.  (May 2015, Beta Blog)
• Effective Two-Drug HIV Regimen Sets Stage for Long-Acting Treatment.  (April 2015, Poz)
• Primate Studies Raise Hope of Eventual Quarterly Injected PrEP.  (January 2015, Poz)
• Injectable rilpivirine shows promise in phase I trials – but may work better for anal than vaginal sex.  (November 2014, AIDSmap)
• Injectable cabotegravir makes progress towards human efficacy studies: doubts about injectable rilpivirine.  (October 2014, AIDSmap)
• Long-Acting, Investigational Integrase Inhibitor Cabotegravir Shows Promise.  (October 2014, TheBody)
• Long-Acting HIV Drugs for Maintenance and PrEP. (March 2014, Beta Blog)
• Early Trial Paves the Way for Study of Long-Acting HIV Meds.  (March 2014, Poz)
• Novel two-drug maintenance combination works at least as well as triple therapy: stage set for long-lasting injectable formulation.  (March 2014, AIDSmap)
• Trial Bodes Well for Long-Acting HIV Drugs. (March 2014, MedPage Today)
• Early Trial Raises Hopes of Quarterly PrEP Injections.  (March 2014, Poz)
• Monkey studies confirm viability of injectable PrEP drug.  (March 2014, AIDSmap)
• Monthly PrEP Injections Show Promise in Female Monkeys.  (March 2014, Poz)
• Long-Acting HIV Drugs Could Extend Lives of Low Adherers.  (November 2013, Poz)
• Long-acting antiretrovirals may improve survival for people with poor adherence.  (October 2013, AIDSmap)
• Long-Acting HIV Antiretrovirals May Be Revolutionary. But Will They Be Worth It?  (October 2013, TheBodyPro)
• Once-a-Month HIV Meds Show Promise in Early Trial.  (July 2013, Poz)
• Long-acting GSK1265744 and TMC278-LA appear safe and practical in early study.  (July 2013, AIDSmap)
• PrEP GSK744 Integrase Administered Monthly Perhaps Quarterly Prevents HIV-Infection in Monkeys.  (March 2013, NATAP)
• Monthly injectable drug offers 100% protection against HIV in monkeys – could be dosed every three months. (March 2013, AIDSmap)